1. Academic Validation
  2. Fatty acid binding protein 3 deficiency limits atherosclerosis development via macrophage foam cell formation inhibition

Fatty acid binding protein 3 deficiency limits atherosclerosis development via macrophage foam cell formation inhibition

  • Exp Cell Res. 2021 Oct 1;407(1):112768. doi: 10.1016/j.yexcr.2021.112768.
Lili Tan 1 Jie Lu 2 Limin Liu 2 Lu Li 2
Affiliations

Affiliations

  • 1 Department of Cardiology, The Central Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning, People's Republic of China; Department of Cardiology, The Second Affiliated Hospital of Shenyang Medical College, Shenyang, Liaoning, People's Republic of China. Electronic address: [email protected].
  • 2 Department of Cardiology, The Second Affiliated Hospital of Shenyang Medical College, Shenyang, Liaoning, People's Republic of China.
Abstract

Atherosclerosis is the underlying contributing factor of Cardiovascular Disease, which is a process of inflammation and lipid-rich lesion. Macrophage-derived foam cell is a key hallmark of atherosclerosis and connected with various factors of lipid metabolism. Here, we showed that fatty acid binding protein 3 (FABP3) was upregulated in the aorta of ApoE-/- mice with high-fat-diet (HFD) feeding. Knockdown of FABP3 in HFD-fed ApoE-/- mice notably facilitated Cholesterol efflux, inhibited macrophage foam cell formation, and thus prevented atherogenesis. Furthermore, FABP3 silencing decreased the expression of Peroxisome Proliferator-activated Receptor γ (PPARγ). Mechanistic studies had disclosed the involvement of PPARγ signaling in balancing Cholesterol uptake and efflux and diminishing foam cell formation. These findings firstly revealed an anti-atherogenic role of FABP3 silencing in preventing foamy macrophage formation partly through PPARγ, which might be a beneficial approach for therapying atherosclerosis.

Keywords

Atherosclerosis; FABP3; Foam cell formation; Macrophage; PPARγ.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-16578
    99.87%, PPARγ Antagonist